Sign in
TerminatedPhase 3

Comparing Between CO2 and Phenylephrine Treatment in Patients With Progressive Lacunar Infarction (CARBOGEN Study)

Key facts

Who runs it
Yonsei University
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 3
People taking part
3 people enrolled
Started
5 Apr 2021
Ended
12 Sept 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • carbogen
  • phenylephrine
Record updated
14 January 2025
Why it stopped
Slow Patient Enrollment

Who can take part

Age
20 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (13)Hide the full registry criteria

Who can take part

  • Age ≥20 years
  • Anterior circulation progressive lacunar infarction
  • Neurological worsening either 1 point in NIHSS score or MRC grade

Who cannot take part

  • Moyamoya disease
  • Difficulty in inhalation of Carbogen (panic, severe anxiety disorder)
  • Drug allergy for phenylephrine
  • History of hemorrhagic stroke
  • Pre-stroke mRS ≥2
  • Age <20
  • Cortical infarction
  • Posterior circulation lacunar infarction
  • Relevant artery stenosis more than 50% or occlusion
  • Persistent bradycardia (pulse rate < 50 /min)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Lacunar infarction is an ischemic stroke occurred by small perforating artery occlusion . Twenty percent of ischemic stroke is lacunar infarction.

Read full original descriptionShow less

However, outcome of lacunar infarction is excellent, about 20-40% patients are suffered neurological worsening.

Progressive lacunar infarction is associated poor functional outcome and neurological deficit.

Currently, no treatment for progressive lacunar infarction is recommended on the guideline.

Several small study reported that phenylephrine and magnesium may be helpful for progressive lacunar infarction.

Carbogen is a mixture of 5% CO2 with 95% O2. Carbogen is safe and it is used for the treatment of sudden sensory neural hearing loss or ocular ischemia.

CO2 dilate cerebral arteriole and concentration of CO2 is correlated with cerebral blood flow.

Lacunar infarction is small and perfused with marginal flow by neighboring perforating arteriole.

Increased cerebral blood flow following dilation of cerebral arteriole by CO2 might halt and revert progressive lacunar infarction.

Induced hypertension is alternative treatment of progressive lacunar infarction. Increasing blood pressure also induce cerebral blood flow.

Phenylephrine is an α1 agonist, phenylephrine act on peripheral artery and little effect on cerebral artery or heart.

Several studies reported that the effectiveness of phenylephrine on progressing stroke.

Therefore, this study will compare the effectiveness of carbogen versus phenylephrine in lacunar infarction patients who suffered neurological worsening.

The 2 groups in the trial

  • Carbogen groupTreatment being tested

    Treatment: carbogen

  • Phenylephrine groupExisting treatment, for comparison

    Treatment: phenylephrine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
14 January 2025